Friday July 3rd, 2020 8:13PM

Merck's global sales jump 12% in second quarter

By The Associated Press
Related Articles
  Contact Editor

Soaring sales of its cancer blockbuster and vaccines helped drive Merck's second-quarter profit up a whopping 54%, blowing past Wall Street expectations.

The maker of cancer immunotherapy drug Keytruda and diabetes pill Januvia also benefited from slightly reduced spending on research and restructuring, even as it becomes a bigger payer in advanced cancer medicines.

The Kenilworth, New Jersey, company raised its revenue forecast for the year by more than $1 billion.

That's despite the fact that Chief Financial Officer Rob Davis made a surprising comment that Merck isn't planning to hike U.S. prices for its drugs anymore to offset declining prices in other countries, as it has for several years.

"We no longer see the benefit of those price increases in the United States because of obviously the changing dynamics. And so as you look in total, we do continue to believe we're going to see declining price as we look forward impacting our margins," Davis said, responding to an analyst's question on a conference call.

Rising drug prices have drawn increasing furor from patients, politicians and advocacy groups, many newly formed, for the past three years, and both Congress and the Trump administration have been proposing various strategies to at least slow the rise of prices and patients' out-of-pocket costs. Drug prices have been an issue in the run-up to prior national elections, but the pressure has not been as sustained as it is today, leaving drugmakers, many of which make up to half their revenue in the U.S., nervous about their future results.

Investors didn't seem upset by the price discussion. In afternoon trading, Merck shares were up 78 cents at $83.26 after jumping as high as $85.17.

Merck reduced its 2018 earnings per share forecast due to a charge for the just-closed acquisition of Peloton Therapeutics.

During the quarter, Merck also bought a second company developing cancer therapies, Tilos Therapeutics, and a third developing ways to boost the immune system to fight diseases.

Until 5 years ago, Merck had little presence in cancer other than Emend for treating nausea and vomiting caused by chemotherapy. But Keytruda's dominance in the market — it's now approved for treating 20 cancer types and patient groups — has shifted much of Merck's research and revenue to oncology.

Keytruda sales jumped 58% to $2.63 billion in the quarter, as the biologic drug continues to rack up more approvals, most recently for patients with advanced small cell lung cancer who've failed other treatments, and as initial treatment for advanced head and neck cancer.

"We estimate Keytruda sales will exceed $16 billion by 2022, driven by continuing uptake within lung cancer and increasing indications into other types of cancers," Edward Jones analyst Ashtyn Evans wrote to investors.

Revenue also is growing from partnerships with other companies to jointly sell Lynparza for ovarian cancer and Lenvima for liver, kidney and thyroid cancer.

Meanwhile, sales continue to wane for older drugs for more common conditions including diabetes, high cholesterol, asthma and allergies.

"Given Merck's strong financial position, we believe the company will continue to supplement its internal drug development with acquisitions," Evans wrote.

Merck CEO Ken Frazier said he doesn't plan megadeals like the one rival Pfizer announced Monday because of their potential to disrupt research and development. Instead, he's looking for smaller deals that easily fit into Merck's portfolio.

The drugmaker reported net income of $2.67 billion, or $1.03 per share. Earnings, adjusted for one-time costs, were $1.30 per share, or 14 cents better than analysts anticipated.

Merck posted revenue of $11.76 billion in the quarter, up 12%.

Its Gardasil vaccine against the cancer-causing human papilloma virus had sales rise 46% to $886 million, and several other vaccines saw higher sales. Former top sellers Januvia and Janumet, pills for Type 2 diabetes, saw sales decline 4% and 9% respectively amid heavy pressure for low prices in the ultracompetitive diabetes field.

Sales of veterinary medicines such as flea-and-tick killer Bravecto increased 3% to $1.12 billion.

Merck now expects full-year earnings in the range of $3.78 to $3.88 per share, down from its April forecast of $4.04 to $4.14. The company forecast revenue in the range of $45.2 billion to $46.2 billion, up from the prior $43.9 billion to $45.1 billion forecast.

___

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2020 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Merck's global sales jump 12% in second quarter
Sales of Merck's Keytruda jump almost 60%, pushing the company past expectations for the second quarter
7:55AM ( 2 minutes ago )
UN says Afghan forces, allies killed most civilians in 2019
UN says more civilians killed by Afghan forces, their allies than by Taliban, other militants in first half of 2019
7:16AM ( 41 minutes ago )
Experts: Event organizers should improve emergency plans
Experts say organizers should take another look at their emergency plans in the wake of the deadly shooting at a California food festival to see if they can make additional safety improvements
7:09AM ( 48 minutes ago )
Associated Press (AP)
Huawei says sales up 23% despite US controls
Huawei says sales up 23% this year despite US controls but Chinese tech giant faces 'difficulties ahead'
6:13AM ( 1 hour ago )
As Trump dives into racial politics, suburban women recoil
As Trump dives into racial politics, suburban women recoil from his abrasive rhetoric
6:05AM ( 1 hour ago )
Hong Kong protesters hit subway to disrupt morning commute
Protesters in Hong Kong have disrupted subway service during the morning commute by blocking the doors on trains, preventing them from leaving the stations
5:49AM ( 2 hours ago )
AP Business
Beyond Meat raises 2019 outlook but shares slump on offering
Beyond Meat raises 2019 outlook after better-than-expected 2Q sales, but shares slump on loss, stock offering
6:09PM ( 13 hours ago )
Pfizer, Mylan strengthen ties, create new company
Pfizer, strengthening ties to Mylan, will pair its off-patent division with the generic drugmaker, creating a new company
5:48PM ( 14 hours ago )
US stocks slip ahead of key Fed meeting, busy earnings week
Major U.S. stock indexes closed mostly lower Monday as investors turned cautious ahead of a key Federal Reserve interest policy announcement and other potentially market-moving developments on tap for this week
4:54PM ( 15 hours ago )
AP Business - Corporate News
Lawsuits stemming from gas explosions settled for $143M
The utility blamed for a series of gas explosions in Massachusetts last September has settled all class action lawsuits resulting from the disaster for $143 million
1:45AM ( 6 hours ago )
Asian shares higher as China-US trade talks set to resume
Asian shares mostly higher as US-Chinese envoys prepare to resume trade talks
12:49AM ( 7 hours ago )
Trump administration, Democrats make progress on new NAFTA
Trump administration, Democrats moving ahead on compromise on revamped North America trade deal
12:30AM ( 7 hours ago )
AP Business - Industries
Despite calls to start over, US health system covers 90%
Despite politicians' calls to start over, the much-maligned US health care system covers 90%
6:55AM ( 2 days ago )
Drug cost bill advances but GOP resistance spells trouble
Bipartisan compromise to reduce drug costs for seniors advances in Senate over GOP resistance
8:15PM ( 4 days ago )
Judge temporarily blocks new Arkansas anti-abortion laws
A federal judge has temporarily stopped three new abortion restrictions from taking effect in Arkansas
3:51PM ( 5 days ago )
AP Business - Health Care
UN says Afghan forces, allies killed most civilians in 2019
UN says more civilians killed by Afghan forces, their allies than by Taliban, other militants in first half of 2019
7:16AM ( 41 minutes ago )
Experts: Event organizers should improve emergency plans
Experts say organizers should take another look at their emergency plans in the wake of the deadly shooting at a California food festival to see if they can make additional safety improvements
7:09AM ( 48 minutes ago )
Merck's global sales jump 12%
Sales of Merck's Keytruda jump almost 60%, pushing the company past expectations for the second quarter
7:00AM ( 57 minutes ago )
2nd Dem debate will be some candidates' last chance to shine
The 2nd set of Democratic presidential debates will be a last chance for some 2020 candidates to be considered serious contenders
6:33AM ( 1 hour ago )
Experts say check emergency plans after festival shooting
Experts say organizers should take another look at their emergency plans in the wake of the deadly shooting at a California food festival to see if they can make additional safety improvements
6:17AM ( 1 hour ago )